Details of the Drug

General Information of Drug (ID: DM7I64Z)

Drug Name

Almogran

Synonyms

Almotriptan; Axert; Almotriptan (USAN); Axert (TN); LAS-31416; PNU-180638; Almotriptan [USAN:INN:BAN]; N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine; N,N-dimethyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine; 1-(((3-(2-(Dimethylamino)ethyl)indol-5-yl)methyl)sulfonyl)pyrrolidine

Indication

Disease Entry	ICD 11	Status	REF
Migraine	8A80	Approved	[1]

Therapeutic Class

Antimigraine Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

335.5

Topological Polar Surface Area (xlogp)

1.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
Bioavailability: 70% of drug becomes completely available to its intended biological destination(s) [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 8.9 mL/min/kg [4]
Elimination: 40% of drug is excreted from urine in the unchanged form [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 3.4 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.0646 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.6% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.2 L/kg [4]

Chemical Identifiers

Formula: C17H25N3O2S
IUPAC Name: N,N-dimethyl-2-[5-(pyrrolidin-1-ylsulfonylmethyl)-1H-indol-3-yl]ethanamine
Canonical SMILES: CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3
InChI: InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
InChIKey: WKEMJKQOLOHJLZ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 123606
ChEBI ID: CHEBI:520985
CAS Number: 154323-57-6
DrugBank ID: DB00918
TTD ID: D0P0SM
ACDINA ID: D00021

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Agonist	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Almogran (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Almogran and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[15]
Oliceridine	DM6MDCF	Moderate	Additive serotonergic effects by the combination of Almogran and Oliceridine.	Acute pain [MG31]	[16]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Almogran caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[17]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Almogran and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[18]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Almogran and Droxidopa.	Autonomic nervous system disorder [8D87]	[19]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Almogran caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[17]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Almogran caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[17]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Almogran caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[17]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Almogran caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[17]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Almogran and Dihydrocodeine.	Chronic pain [MG30]	[16]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Almogran and Levomilnacipran.	Chronic pain [MG30]	[18]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Almogran and Sertraline.	Depression [6A70-6A7Z]	[18]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Almogran and Vilazodone.	Depression [6A70-6A7Z]	[18]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Almogran and Nefazodone.	Depression [6A70-6A7Z]	[18]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Almogran and Vortioxetine.	Depression [6A70-6A7Z]	[18]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Almogran and Isocarboxazid.	Depression [6A70-6A7Z]	[15]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Almogran and Milnacipran.	Depression [6A70-6A7Z]	[18]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Almogran and Escitalopram.	Depression [6A70-6A7Z]	[18]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Almogran and Desvenlafaxine.	Depression [6A70-6A7Z]	[18]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Almogran and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[20]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Almogran caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Almogran caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[17]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Almogran caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[17]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Almogran caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[17]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Almogran caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[17]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Almogran caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[22]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Almogran and Procarbazine.	Hodgkin lymphoma [2B30]	[15]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Almogran caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Almogran caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Almogran caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Almogran caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Almogran caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Almogran caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[17]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Almogran caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[24]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Almogran caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[17]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Almogran caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[25]
Ozanimod	DMT6AM2	Major	Additive serotonergic effects by the combination of Almogran and Ozanimod.	Multiple sclerosis [8A40]	[26]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Almogran caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[27]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Almogran and Sibutramine.	Obesity [5B80-5B81]	[15]
Lorcaserin	DMG6OYJ	Major	Additive serotonergic effects by the combination of Almogran and Lorcaserin.	Obesity [5B80-5B81]	[28]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Almogran and Dexfenfluramine.	Obesity [5B80-5B81]	[18]
Levomethadyl Acetate	DM06HG5	Moderate	Additive serotonergic effects by the combination of Almogran and Levomethadyl Acetate.	Opioid use disorder [6C43]	[16]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of Almogran and Oxymorphone.	Pain [MG30-MG3Z]	[16]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Almogran and Dezocine.	Pain [MG30-MG3Z]	[16]
Buprenorphine	DMPRI8G	Moderate	Additive CNS depression effects by the combination of Almogran and Buprenorphine.	Pain [MG30-MG3Z]	[16]
Hydrocodone	DMQ2JO5	Moderate	Additive serotonergic effects by the combination of Almogran and Hydrocodone.	Pain [MG30-MG3Z]	[16]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Almogran caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[29]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Almogran caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[30]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Almogran caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[17]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Almogran and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[31]
Armodafinil	DMGB035	Minor	Increased metabolism of Almogran caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[32]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Almogran caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[33]
-----------


⏷ Show the Full List of 52 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium stearyl fumarate	E00545	23665634	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Almotriptan 12.5 mg tablet	12.5 mg	Oral Tablet	Oral
Almotriptan 6.25 mg tablet	6.25 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drug information of Almogran, 2008. eduDrugs.
2	BDDCS applied to over 900 drugs
3	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
7	Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
10	An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
11	Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
12	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
13	Company report (NeurAxon)
14	Company report (Fabrekramer)
15	Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
16	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
17	Product Information. Axert (almotriptan) Pharmacia and Upjohn, Kalamazoo, MI.
18	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
19	Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
20	Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
23	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
24	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
25	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
26	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
27	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
28	Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
29	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
30	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
31	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
32	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
33	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.